leading technologies
for innovative medicine

Company Onco Genotest
develops technologies for personalized treatment of oncological diseases by investigation genomic data.
Our aim
is application of OMICs technologies and current knowledge of oncogenesis in clinical practice.

How molecular profiling of tumor can help to treat cancer?

Accumulation of mutations

in oncogenes and genes-suppressors can lead to developing of cancer by alteration of intracellular metabolism, proliferation, cell death and cellular interplay. Such cell's modifications are responsible for growth of tumor.

These mutations

have clinical significance for progress of disease, associated with effectiveness of different treatment options and, therefore, are regarded as biomarkers.

Biomarker is a result of analysis,

which has definite prognostic and predictive meaning. Today there are a lot of drugs on market, which target specific molecular changes (biomarkers) in cancer cells (target treatment). Furthermore, recent investigations demonstrate that effectiveness of standard chemotherapy also depends on molecular profile of tumor

The currently challenge is

not only in necessity of developing new therapeutic agents, but also in problems of sensible using different drugs for every patient and overcoming resistance to various treatment options.

Personalized medicine is

a new therapeutic approach involving the use of an individual’s genetic and epigenetic information, environment conditions and patient’s lifestyle to tailor drug therapy or preventive care. In oncology personalized treatment includes using tumor's molecular profile for diagnosis, creation of therapy plan and assessment of treatment effectiveness.

Tumor molecular profiling

Consultation

Consultation includes: indications for molecular-genetic analysis; collection of data about patient and anamnesis morbi; collection of samples or analysis (biopsy and liquid biopsy)

Confirmation of diagnosis

Histological confirmation of diagnosis

Development of molecular profile

Development of molecular profile (NGS; IHC)

Processing of data

Bioinformatic and system biology processing of data

Complex conclusion:

Complex conclusion: individual molecular profile, potential sensitive\resistance to different treatment options, clinical trials, mechanisms of cancerogenesis

Creation of complex molecular profile of tumor

Consultation

Confirmation of diagnosis

Development of molecular profile

Processing of data

Complex conclusion

Histological confirmation of diagnosis
Development of molecular profile (NGS; IHC)
Bioinformatic and system biology processing of data
Complex conclusion: individual molecular profile, potential sensitive\resistance to different treatment options, clinical trials, mechanisms of cancerogenesis
Consultation includes: indications for molecular-genetic analysis; collection of data about patient and anamnesis morbi; collection of samples or analysis (biopsy and liquid biopsy)

Bioinformatic platform

Comprehensive database

includes knowledge about all clinically significant biomarkers, clinical trials, pharmacogenomics and signal pathways. Database regularly updated from approved sources. All data is stored in cloud storage and good guarded.

Platform enables

to provide complex analysis of different types of biomarkers, including data about anamnesis morbi, histological characteristics of tumor, NGS, IHC and other diagnostic options

Special attention

was given to the most accurate detection of molecular alterations by using of the latest versions of bioinformatic software. By using of neural networks and deep learning we develop proprietary algorithm for analysis of associations between molecular profile of tumor and potential effectiveness of treatment.

Our unique platform

implements the principles of precision medicine and provides oncologists with wide summary of data for the best treatment option.

TEAM

Rabaev Gavriil

Director for Scientific Development

Pyatnitskiy Mikhail

Bioinformatician
System biologist,
Ph.D.

Rabaev Gennady

Mentor, Oncologist, Surgeon

Bavikin Andrey

System biologist

Fedotov Valeriy

Lead Developer

Lavrentev Ivan

Blockchain Developer

Rabaeva Liana

CEO

Kasatskiy Aleksandr

CFO

Glaziev Ruslan

Executive Director

Tusaev Dmitriy

Front-end Developer

Kostin Vadim

Front-end Developer

News

Contacts

Address

Russia, 125047, Moscow, 1-ya Brestskaya, 33

Treatment of cancer requires a team approach. We will be glad to communicate and create an interdisciplinary consilium for solving medical and scientific issues.